Literature DB >> 33673113

Natural Progression of Non-Alcoholic Steatohepatitis to Hepatocellular Carcinoma.

Daryl Ramai1, Waqqas Tai1, Michelle Rivera1, Antonio Facciorusso2, Nicola Tartaglia3, Mario Pacilli3, Antonio Ambrosi3, Christian Cotsoglou4, Rodolfo Sacco2.   

Abstract

Non-alcoholic steatohepatitis (NASH) is a chronic and progressive form of non-alcoholic fatty liver disease (NAFLD). Its global incidence is increasing which makes NASH an epidemic and a public health threat. Due to repeated insults to the liver, patients are at risk for developing hepatocellular carcinoma (HCC). The progression of NASH to HCC was initially defined according to a two-hit model which involved the development of steatosis, followed by lipid peroxidation and inflammation. However, current research defines a "multi-hit" or "multi-parallel hit" model which synthesizes several contributing pathways involved in progressive fibrosis and oncogenesis. This perspective considers the effects of cellular, genetic, immunologic, metabolic, and endocrine pathways leading up to HCC which underscores the complexity of this condition. This article will provide an updated review of the pathogenic mechanisms leading from NASH to HCC as well as an exploration of the role of biomarkers and screening.

Entities:  

Keywords:  hepatocellular carcinoma; non-alcoholic steatohepatitis; pathogenesis

Year:  2021        PMID: 33673113     DOI: 10.3390/biomedicines9020184

Source DB:  PubMed          Journal:  Biomedicines        ISSN: 2227-9059


  3 in total

1.  Accumulation of Genetic and Epigenetic Alterations in the Background Liver and Emergence of Hepatocellular Carcinoma in Patients with Non-Alcoholic Fatty Liver Disease.

Authors:  Satoru Hagiwara; Naoshi Nishida; Kazuomi Ueshima; Yasunori Minami; Yoriaki Komeda; Tomoko Aoki; Masahiro Takita; Masahiro Morita; Hirokazu Chishina; Akihiro Yoshida; Hiroshi Ida; Masatoshi Kudo
Journal:  Cells       Date:  2021-11-21       Impact factor: 6.600

Review 2.  Progressive Liver Fibrosis in Non-Alcoholic Fatty Liver Disease.

Authors:  Daryl Ramai; Antonio Facciorusso; Erika Vigandt; Bryan Schaf; Waleed Saadedeen; Aditya Chauhan; Sara di Nunzio; Aashni Shah; Luca Giacomelli; Rodolfo Sacco
Journal:  Cells       Date:  2021-12-02       Impact factor: 6.600

3.  NASH and Systemic Complications: From Basic to Clinical Research.

Authors:  Sabine Baumgartner; Ronit Shiri-Sverdlov
Journal:  Biomedicines       Date:  2021-12-14
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.